The role of Claudin-6 in chromophobe renal cell carcinoma.

BACKGROUND The prognostic value of Claudin-6 (CLDN6) in non clear cell renal cell carcinoma (RCC) is still unclear. AIM To evaluate the prognostic impact of CLDN6 expression in a large cohort of chromophobe RCC (chRCC). MATERIAL AND METHODS Patients who underwent renal surgery due to chRCC were recruited. Clinical data were retrospectively evaluated. Tumor specimens were analyzed for CLDN6 expression by immunohistochemistry. RESULTS 81 chRCC patients were eligible for analysis, thereof 10 (12.3%) patients were positive for CLDN6. No significant associations were found for CLDN6 expression and clinical attributes in patients with chRCC. Kaplan-Meier analysis revealed no differences in overall survival (OS) for patients with CLDN6⁻ compared to CLDN6⁺ tumors (87.0% versus 62.5%; p=0.174). CONCLUSION In chRCC CLDN6 expression is not associated with parameters of aggressiveness or survival. Due to the rare incidence of chRCC further studies with larger cohorts are warranted.

[1]  M. Stöckle,et al.  The prognostic impact of Claudin 6 in papillary renal cell carcinoma. , 2022, Pathology, research and practice.

[2]  Qi Zhao,et al.  Identification of Claudin-6 as a Molecular Biomarker in Pan-Cancer Through Multiple Omics Integrative Analysis , 2021, Frontiers in Cell and Developmental Biology.

[3]  Yuta Endo,et al.  Prognostic Significance of Aberrant Claudin-6 Expression in Endometrial Cancer , 2020, Cancers.

[4]  T. Miyazaki,et al.  Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme , 2019, Virchows Archiv.

[5]  Xin Zhou,et al.  Expression of CLDN6 in tissues of gastric cancer patients: Association with clinical pathology and prognosis , 2019, Oncology letters.

[6]  C. Fletcher,et al.  Claudin-4 expression distinguishes SWI/SNF complex-deficient undifferentiated carcinomas from sarcomas , 2017, Modern Pathology.

[7]  R. Verhaak,et al.  Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. , 2015, Cancer research.

[8]  Qiang Wang,et al.  Low claudin-6 expression correlates with poor prognosis in patients with non-small cell lung cancer , 2015, OncoTargets and therapy.

[9]  F. Pontén,et al.  Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non‐small‐cell lung cancer , 2014, International journal of cancer.

[10]  Y. Doki,et al.  Prognostic Impact of Major Receptor Tyrosine Kinase Expression in Gastric Cancer , 2014, Annals of Surgical Oncology.

[11]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[12]  B. Kleinschmidt-DeMasters,et al.  Claudin 6 Is a Positive Marker for Atypical Teratoid/Rhabdoid Tumors , 2010, Brain pathology.

[13]  R. Tavares,et al.  The diagnostic and prognostic utility of claudin expression in renal cell neoplasms , 2008, Modern Pathology.

[14]  A. Young,et al.  Claudin-7 and claudin-8: immunohistochemical markers for the differential diagnosis of chromophobe renal cell carcinoma and renal oncocytoma. , 2009, Human pathology.

[15]  B. Murer,et al.  Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions , 2007, Virchows Archiv.

[16]  P. Morin,et al.  Claudin proteins in human cancer: promising new targets for diagnosis and therapy. , 2005, Cancer research.

[17]  K. Fujimoto,et al.  A Single Gene Product, Claudin-1 or -2, Reconstitutes Tight Junction Strands and Recruits Occludin in Fibroblasts , 1998, The Journal of cell biology.

[18]  Jian Li.  Targeting claudins in cancer: diagnosis, prognosis and therapy. , 2021, American journal of cancer research.